Intraocular Amphiregulin antibody and axial elongation in nonhuman primates

Wenyao Wang, Nan Yan, Tiejun Huang, Mingliang Pu, Jost B. JonasFrontiers in Ophthalmology 2022 · DOI

Abstract

Intraocularly applied amphiregulin antibody (100μg) reduced the physiological ocular axial elongation in juvenile nonhuman primates.

Introduction: The Myopia Challenge

Axial myopia occurs when the eyeball grows too long from front to back, a process known as axial elongation. This stretching is the primary cause of nearsightedness and, in severe cases, can lead to irreversible blindness through retinal detachment or myopic maculopathy. While environmental factors play a role, the molecular signaling pathways that drive this growth are still being identified.

Previous research in rodent models suggested that the Epidermal Growth Factor (EGF) family, specifically a protein called amphiregulin, stimulates the growth of the eye's outer layers. This study bridges the gap to human biology by testing whether blocking amphiregulin can stop eye growth in nonhuman primates, whose ocular anatomy and development closely mimic our own.

Methods

Researchers conducted an experimental study using six juvenile male macaque monkeys (Macaca fascicularis), aged 11–12 months.

  • Experimental Group (n=3): These monkeys received three intravitreal injections of an amphiregulin antibody (100µg) in their left eyes at intervals of 4–6 weeks. Their right eyes received a neutral phosphate-buffered solution (PBS) as an internal control.
  • Blank Control Group (n=3): These monkeys received no injections to provide a baseline for natural, physiological eye growth.

Over 24 weeks, the team used sonographic biometry to measure axial length and vitreous cavity length, while also monitoring intraocular pressure and retinal health for signs of toxicity.

Impact on Axial Growth

The study found that the amphiregulin antibody effectively halted physiological eye growth. In the experimental group, treated left eyes showed no significant change in axial length (18.91 mm to 18.94 mm), while the untreated right eyes in the same animals grew significantly (18.87 mm to 19.24 mm).

Interocular difference in axial elongation between experimental and control groups.

By the end of the study, the interocular difference in the experimental group was significant (-0.34 ± 0.15 mm) compared to the negligible difference in the control group (0.03 ± 0.08 mm). The reduction in axial length was most strongly correlated with a reduction in the growth of the vitreous cavity, suggesting the antibody prevents the "stretching" of the posterior segment of the eye.

Clinical Correlation and Safety

The physical reduction in axial length translated directly to refractive outcomes. The smaller axial length in treated eyes was inversely associated with refractive error, meaning the treated eyes remained less "nearsighted" than the controls throughout the follow-up period.

Association between interocular differences in refractive error and axial length across follow-up examinations.

Importantly, the treatment demonstrated a strong safety profile. No signs of ocular toxicity, inflammation, or changes in intraocular pressure were observed, suggesting that targeted EGF-family blockade might be a safe pharmacological intervention for myopia.

Limitations and Future Directions

While these results are promising, the study's small sample size (n=6) requires confirmation in larger cohorts. Additionally, this study focused on natural eye growth; future research must determine if the antibody is equally effective at stopping accelerated growth caused by environmental factors (lens-induced myopia). Finally, while intravitreal injections were used here, future work may explore less invasive delivery methods, such as topical eye drops.

Summary updated

Abstract

Intraocularly applied amphiregulin antibody (100μg) reduced the physiological ocular axial elongation in juvenile nonhuman primates.
BibTeX
@inproceedings{wang2022intraocular,
  author = {Wenyao Wang and Nan Yan and Tiejun Huang and Mingliang Pu and Jost B. Jonas},
  title = {{Intraocular Amphiregulin antibody and axial elongation in nonhuman primates}},
  booktitle = {Frontiers in Ophthalmology},
  year = {2022},
  doi = {10.3389/fopht.2022.995157},
}
Figure